Analyst Price Targets — PRCT
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| February 27, 2026 6:03 pm | Richard Newitter | Truist Financial | $30.00 | $22.69 | StreetInsider | Procept BioRobotics Corp (PRCT) PT Lowered to $30 at Truist Securities |
| February 26, 2026 10:58 am | Nathan Treybeck | Wells Fargo | $34.00 | $27.84 | StreetInsider | Procept BioRobotics Corp (PRCT) PT Lowered to $34 at Wells Fargo |
| December 18, 2025 2:14 pm | Richard Newitter | Truist Financial | $47.00 | $34.24 | TheFly | Procept BioRobotics price target lowered to $47 from $50 at Truist |
| December 12, 2025 5:57 am | Danielle Antalffy | UBS | $62.00 | $36.02 | StreetInsider | UBS Starts Procept BioRobotics Corp (PRCT) at Buy |
| December 2, 2025 11:34 am | Patrick Wood | Morgan Stanley | $51.00 | $30.41 | TheFly | Procept BioRobotics price target lowered to $51 from $56 at Morgan Stanley |
| November 5, 2025 2:23 pm | Matt O'Brien | Piper Sandler | $50.00 | $32.80 | TheFly | Procept BioRobotics price target lowered to $50 from $55 at Piper Sandler |
| November 5, 2025 11:19 am | Mike Kratky | Leerink Partners | $55.00 | $35.02 | StreetInsider | Procept BioRobotics Corp (PRCT) PT Lowered to $55 at Leerink Partners |
| November 5, 2025 11:18 am | — | Wells Fargo | $51.00 | $35.02 | TheFly | Procept BioRobotics price target lowered to $51 from $58 at Wells Fargo |
| October 15, 2025 12:46 pm | — | Truist Financial | $50.00 | $34.11 | TheFly | Procept BioRobotics price target lowered to $50 from $64 at Truist |
| September 2, 2025 10:05 am | Suraj Kalia | Oppenheimer | $60.00 | $41.58 | StreetInsider | Oppenheimer Upgrades Procept BioRobotics Corp (PRCT) to Outperform |
Latest News for PRCT
SAN JOSE, Calif., April 09, 2026 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (the “Company”) (Nasdaq: PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced it will report financial results for the first quarter of 2026 after market close on Wednesday, April 29, 2026. The Company's management will host a corresponding…
OPKO Health (NASDAQ: OPK - Get Free Report) and PROCEPT BioRobotics (NASDAQ: PRCT - Get Free Report) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, dividends, institutional ownership, risk, valuation, earnings and analyst recommendations. Earnings and Valuation This table compares OPKO
SG Americas Securities LLC boosted its stake in PROCEPT BioRobotics Corporation (NASDAQ: PRCT) by 142.0% in the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 84,294 shares of the company's stock after purchasing an additional 49,457 shares during the
Procept BioRobotics reported one set of numbers to investors -- the actual figures told a different story NEW YORK, April 1, 2026 /PRNewswire/ -- Investors in Procept BioRobotics (NASDAQ: PRCT) lost more than 15% of their investment value after the Company disclosed financial results that diverged sharply from the figures management had presented. Those who suffered losses are encouraged to submit their information…
PROCEPT BioRobotics is rated buy, offering a unique, FDA-cleared Aquablation platform for BPH, targeting a large, underpenetrated market. PRCT trades at 2.9x forward EV/2026E revenue, a deep discount to peers, despite 27-33% guided revenue growth and improving margins. A recent Q4 revenue miss and rebate changes triggered a 63% stock drop, but fundamentals remain strong with $286M cash and minimal dilution risk.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for PRCT.
U.S. House Trading
No House trades found for PRCT.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.